Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026)

Vanda Pharmaceuticals has disclosed Cash from Operations across 17 years of filings, most recently posting 50218000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 50218000.0, down 51.5% year-over-year; the trailing twelve-month figure through Mar 2026 was 126513000.0 (down 124.02% YoY), and the FY2025 annual result was 109442000.0, down 594.56% from the prior year.
• Cash from Operations came in at 50218000.0 for Q1 2026 at Vanda Pharmaceuticals, down from 29417000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 31803000.0 in Q1 2023 to a low of 50218000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 3732000.0 (2023), against an average of 7684235.29.
• Across the five-year window, Cash from Operations soared 686.04% in 2023 and tumbled 1518.99% in 2025, its largest moves.
• Vanda Pharmaceuticals' Cash from Operations stood at 9416000.0 in 2022, then slumped by 139.63% to 3732000.0 in 2023, then surged by 51.31% to 1817000.0 in 2024, then sank by 1518.99% to 29417000.0 in 2025, then plunged by 70.71% to 50218000.0 in 2026.
• The last three Cash from Operations figures came in at 50218000.0 (Q1 2026), 29417000.0 (Q4 2025), and 31626000.0 (Q3 2025), per Business Quant data.